

- Level 1 FDA-approved device
 Approved CMS RTM/PCM billing opportunity
- + HIPAA compliant
- Pump agnostic
- + 24/7 case management and support
- In clinical trials with University of Oklahoma Medical Center

IV Infusion technology that reduces readmission rates and promotes predictable healthcare value on Day 1

Readmission rates due to IV antibiotic nonadherence affects the entire healthcare continuum, costs payers \$290 billion annually, and negatively impacts patient outcomes. IV Ensure™ is the first-ever, pump-agnostic cellular technology that tracks, case manages, and reports adherence rates for chronically ill patients in the home, driving readmission rates down and health value up for hospitals, pharmacies, and payers. IVE is the wrap-around solution to ensure post-acute patient infusion adherence.







The Future of Home Infusion

IV Ensure™ uses a patented IV monitoring device, in-depth patient analytics, and case management to ensure your patients stay adherent and connected to their care team.



How does IVE work to decrease readmissions?

- Drives patient adherence (push, elasto, pump)
- Allows health managers (including prescribing providers, managing pharmacists, payors, and disease management companies) access to data streams to maximize decision making
- Creates an integrated, accountable caregiver team from nurses to providers to patients
- Reduces readmissions = more home care days and less re-authorizations

Email mitchell@ivensure.com or visit ivensure.com to learn more.

